Ponatinib Inhibits Multiple Signaling Pathways Involved in STAT3 Signaling and Attenuates Colorectal Tumor Growth

Signal transducer and activator of transcription 3 (STAT3) signaling is a major driver of colorectal cancer (CRC) growth, however therapeutics, which can effectively target this pathway, have so far remained elusive. Here, we performed an extensive screen for STAT3 inhibitors among a library of 1167 FDA-approved agents, identifying Ponatinib as a lead candidate. We found that Ponatinib inhibits STAT3 activity driven by EGF/EGFR, IL-6/IL-6R and IL-11/IL-11R, three major ligand/receptor systems involved in CRC development and progression. Ponatinib was able to inhibit CRC migration and tumor growth in vivo. In addition, Ponatinib displayed a greater ability to inhibit STAT3 activity and mediated superior anti-proliferative efficacy compared to five FDA approved SRC and Janus Kinase (JAK) inhibitors. Finally, long-term exposure of CRC cells to Ponatinib, Dasatinib and Bosutinib resulted in acquired resistance to Dasatinib and Bosutinib occurring within six weeks. However, acquired resistance to Ponatinib was observed after long-term exposure of >4 months. Overall, our results identify a novel anti-STAT3 property of Ponatinib and thus, Ponatinib offers a potential therapeutic strategy for CRC.

[1]  D. Tu,et al.  Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial. , 2018, The lancet. Gastroenterology & hepatology.

[2]  Heiner Koch,et al.  The target landscape of clinical kinase drugs , 2017, Science.

[3]  J. Grandis,et al.  EGFR-targeted therapies in the post-genomic era , 2017, Cancer and Metastasis Reviews.

[4]  A. Jemal,et al.  Colorectal cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[5]  Ross Camidge,et al.  Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  F. Bertucci,et al.  Pregnane X-receptor promotes stem cell-mediated colon cancer relapse , 2016, Oncotarget.

[7]  F. Bertucci,et al.  Autocrine Secretion of Progastrin Promotes the Survival and Self-Renewal of Colon Cancer Stem-like Cells. , 2016, Cancer research.

[8]  E. Gratton,et al.  Quantifying the dynamics of the oligomeric transcription factor STAT3 by pair correlation of molecular brightness , 2016, Nature Communications.

[9]  S. Oh,et al.  STAT3-mediated IGF-2 secretion in the tumour microenvironment elicits innate resistance to anti-IGF-1R antibody , 2015, Nature Communications.

[10]  L. Love-Homan,et al.  Upregulated interleukin‐6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma , 2015, Molecular oncology.

[11]  G. Superti-Furga,et al.  A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis , 2015, Cell Death and Disease.

[12]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[13]  J. Fletcher,et al.  Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients , 2014, Clinical Cancer Research.

[14]  Ho-June Lee,et al.  Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. , 2014, Cancer cell.

[15]  Liam O'Connor,et al.  Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer. , 2014, Cancer research.

[16]  Suzanne F. Jones,et al.  Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors , 2014, Cancer Chemotherapy and Pharmacology.

[17]  S. Stylli,et al.  Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity , 2014, Cancer biology & therapy.

[18]  T. Clackson,et al.  A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. , 2013, The New England journal of medicine.

[19]  A. Martínez-Torteya,et al.  SurvExpress: An Online Biomarker Validation Tool and Database for Cancer Gene Expression Data Using Survival Analysis , 2013, PloS one.

[20]  O. Sieber,et al.  Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. , 2013, Cancer cell.

[21]  John Cowell,et al.  Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1. , 2013, Oncology reports.

[22]  M. Santoro,et al.  Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. , 2013, The Journal of clinical endocrinology and metabolism.

[23]  T. Naoe,et al.  Combination of Ponatinib with Hedgehog Antagonist Vismodegib for Therapy-Resistant BCR-ABL1–Positive Leukemia , 2013, Clinical Cancer Research.

[24]  J. Hecht,et al.  Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. , 2012, The Lancet. Oncology.

[25]  I. Flinn,et al.  Ponatinib in refractory Philadelphia chromosome-positive leukemias. , 2012, The New England journal of medicine.

[26]  Simion I. Chiosea,et al.  First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. , 2012, Cancer discovery.

[27]  E. Vokes,et al.  Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium , 2012, Investigational New Drugs.

[28]  J. Christensen,et al.  Activation of IL-6R/JAK1/STAT3 Signaling Induces De Novo Resistance to Irreversible EGFR Inhibitors in Non–Small Cell Lung Cancer with T790M Resistance Mutation , 2012, Molecular Cancer Therapeutics.

[29]  D. Sargent,et al.  Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. , 2012, JAMA.

[30]  T. Clackson,et al.  Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models , 2012, Molecular Cancer Therapeutics.

[31]  C. Bokemeyer,et al.  Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  T. Clackson,et al.  Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies , 2011, Molecular Cancer Therapeutics.

[33]  T. Clackson,et al.  Structural Mechanism of the Pan‐BCR‐ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance , 2011, Chemical biology & drug design.

[34]  Josep Tabernero,et al.  Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  T. Clackson,et al.  AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. , 2009, Cancer cell.

[36]  Enrico Gratton,et al.  Mapping the Number of Molecules and Brightness in the Laser Scanning Microscope , 2007, Biophysical journal.

[37]  Wan-Wan Lin,et al.  A cytokine-mediated link between innate immunity, inflammation, and cancer. , 2007, The Journal of clinical investigation.

[38]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[39]  J. Baselga,et al.  The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy , 2006, Clinical Cancer Research.

[40]  Kurt Zatloukal,et al.  Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. , 2005, Neoplasia.

[41]  R. Jove,et al.  Stat3 regulates genes common to both wound healing and cancer , 2005, Oncogene.

[42]  Donna Neuberg,et al.  Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. , 2005, Cancer cell.

[43]  Ping Chen,et al.  Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.

[44]  T. Hickish,et al.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.

[45]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[46]  R. Schilsky,et al.  Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials , 2004, British Journal of Cancer.

[47]  R. Jove,et al.  Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[49]  A. Scott,et al.  Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. , 2001, Cancer research.

[50]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[51]  R. James,et al.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.

[52]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[53]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[54]  R. Jove,et al.  Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. , 1995, Science.

[55]  G. Stark,et al.  A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin‐6. , 1995, The EMBO journal.

[56]  F. Penault-Llorca,et al.  Impact of EGFR expression on colorectal cancer patient prognosis and survival. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[57]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[58]  R. Gale,et al.  Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis , 2015, OncoTargets and Therapy.